Overview

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Status:
RECRUITING
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.
Phase:
PHASE3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.